Bristol-Myers Squibb Company (BMY)
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.
Scored against other Healthcare stocks, not a fixed scale.
The quick read
Bristol-Myers Squibb leans bullish right now: more is going right than wrong.
- What's working
- It's priced lower than most other healthcare companies, relative to its sales and profits.
- Worth watching
- No major weak spots stand out in the data right now.
Analyst price target
~12-month · 24 analystsPublished targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
About Bristol-Myers Squibb Company
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications…
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Employees
- 32,500
- Headquarters
- Princeton, NJ
Similar stocks
What’s behind the score
Valuation
P/E 13.2 — lower than 93% of Healthcare peers
P/B 5.5 — lower than 36% of Healthcare peers
P/S 2.5 — lower than 70% of Healthcare peers
EV/EBITDA 8.2 — lower than 90% of Healthcare peers
EV/Revenue 3.2 — lower than 70% of Healthcare peers
FCF yield 6.6% — higher than 83% of Healthcare peers
Profitability & quality
Gross margin 71.7% — higher than 73% of Healthcare peers
Operating margin 34.4% — higher than 83% of Healthcare peers
Net margin 18.9% — higher than 77% of Healthcare peers
ROE 46.6% — higher than 89% of Healthcare peers
ROA 10.7% — higher than 79% of Healthcare peers
Free cash flow is 87% of reported net income
Financial health
Debt/equity 2.0 — lower than 7% of Healthcare peers
Current ratio 1.53 — higher than 55% of Healthcare peers
Quick ratio 1.29 — higher than 76% of Healthcare peers
Cash/debt 0.25 — higher than 66% of Healthcare peers
Debt/EBITDA 2.38 — lower than 52% of Healthcare peers
Growth
Revenue growth 5.7% YoY — higher than 33% of Healthcare peers
Earnings growth 153.1% YoY — higher than 92% of Healthcare peers
Ownership & investor activity
Payout ratio 55.3% — somewhat unusual vs Healthcare peers
Net insider buying, +4.2% of insider shares
Institutions net sold, -11.9% of shares held
Insiders hold 0.1% of shares outstanding
2.3% of float sold short
Momentum
Mixed vs its moving averages
66% of the way from its 52-week low to high